Who Paid My Doc
A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu
Research payments
$570,548
Through program year 2022, $570,548 in research payments was reported against A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu, across 76 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $50,683 | 4 |
| 2021 | Research | $255,717 | 47 |
| 2020 | Research | $244,394 | 24 |
| 2019 | Research | $19,754 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jeff Bullock Boerne, TX Named on 11 payments
- Nicholas Karyotakis Los Angeles, CA Named on 5 payments
- Gilbert Simoni Thousand Oaks, CA Named on 5 payments
- Zeid Kayali North Las Vegas, NV Named on 4 payments
- Calin Arimie Northridge, CA Named on 3 payments
- John Weber MacOmb, MI Named on 3 payments
- Ronald Fogel Chesterfield, MI Named on 3 payments
- Orlando Torres Hialeah, FL Named on 3 payments
- Amir Rezk Rock Hill, SC Named on 3 payments
- James Maher Houston, TX Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.